Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Michael Sala

Ophthalmology Erie, PA Doctor of Osteopathy

NPI 1891836722 CMS profile 267410

128 W 12Th St, Ste 200, Erie, PA 16501

Open in the dashboard

General payments

$3,515

88 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Michael Sala of Erie, PA is reported in the CMS Open Payments database as having received $3,515 across 88 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 73rd percentile of Ophthalmology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $717 14
2024 General $361 9
2023 General $365 11
2022 General $119 7
2021 General $440 16
2020 General $158 9
2019 General $1,354 22

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Sala
  • Ophthalmology median
  • Middle half of Ophthalmology
  • National median

In program year 2025, general payments to Michael Sala were reported at $717. Among 13,034 Ophthalmology profiles paid that year, the median was $384 and the middle half received between $136 and $917.

Show as a table
Year Michael Sala Ophthalmology median Middle half National median
2019 $1,354 $258 $104–$655 $163
2020 $158 $126 $45–$321 $114
2021 $440 $205 $76–$534 $132
2022 $119 $266 $100–$678 $149
2023 $365 $308 $117–$745 $160
2024 $361 $340 $127–$846 $164
2025 $717 $384 $136–$917 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. TissueTech, Inc. $669 6 payments
  2. Apellis Pharmaceuticals, Inc. $458 4 payments
  3. Allergan Inc. $384 17 payments
  4. Sun Pharmaceutical Industries Inc. $324 13 payments
  5. Bausch & Lomb, a division of Bausch Health US, LLC $286 12 payments
  6. Novartis Pharmaceuticals Corporation $157 3 payments
  7. Dompe US, Inc. $153 2 payments
  8. Aerie Pharmaceuticals, Inc. $152 4 payments
  9. Omeros Corporation $139 2 payments
  10. Bausch & Lomb Americas Inc. $127 3 payments
  11. Other $667 22 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,908 86 payments
  2. Travel and Lodging $607 2 payments
Products named General payments · program years 2019–2025
  1. Prokera $669 6 payments
  2. AmnioGraft $669 6 payments
  3. AmnioGuard $669 6 payments
  4. Syfovre $333 3 payments
  5. Cequa $324 13 payments
  6. VYZULTA $236 9 payments
  7. LUMIGAN Ophthalmology $171 6 payments
  8. OXERVATE $153 2 payments
  9. Omidria $139 2 payments
  10. LUMIGAN Ophthalmology $139 5 payments
  11. Other $2,019 73 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 21 drugs

Part D claims

2,116

Median for Ophthalmology: 891

Drug cost

$250,229

Median for Ophthalmology: $68,233

Branded share of claims

37%

Median for Ophthalmology: 29.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Lumigan Bimatoprost Brand 232 $73,321
Restasis Cyclosporine Brand 54 $71,601
Cyclosporine Generic 35 $25,379
Simbrinza Brinzolamide/Brimonidine Tart Brand 49 $13,252
Alphagan P Brimonidine Tartrate Brand 40 $12,914
Brimonidine Tartrate-Timolol Brimonidine Tartrate/Timolol Brand 87 $9,959
Combigan Brimonidine Tartrate/Timolol Brand 32 $8,492
Vyzulta Latanoprostene Bunod Brand 23 $7,671
Prednisolone Acetate Generic 157 $7,530
Latanoprost Generic 769 $4,790

The 10 drugs with the highest cost, of 21 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,260 Part D prescribers listed as Ophthalmology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 27 billing codes

Paid by Medicare

$91,923

Medicare's payments for the services billed

Medicare patients

705

Average age 72

Services billed

1,415

401 women, 304 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Arthritis 47%
Diabetes 38%
Ischemic heart disease 25%
Depression 23%
Chronic kidney disease 21%
Atrial fibrillation 16%
COPD 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 7 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Syfovre
  • Apellis Pharmaceuticals, Inc. $107
$107 — —
Cequa
  • Sun Pharmaceutical Industries Inc. $61
$61 — —
MIEBO
  • Bausch & Lomb Americas Inc. $51
$51 — —
XIIDRA
  • Bausch & Lomb Americas Inc. $51
$51 — —
TEPEZZA
  • Amgen Inc. $47
$47 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 7 in the dashboard with a free account

Records

88 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Ophthalmology in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record